A phase II trial of alternating i.v. and oral vinorelbine in combination with cisplatin was designed to determine the response rate, safety profile, progression-free survival, overall survival and quality of life (QoL) in advanced non-small-cell lung cancer (NSCLC).
Introduction
Lung cancer is a public health problem worldwide [1] . Non-smallcell lung cancer (NSCLC) accounts for ∼80% of all lung cancer cases. Patients amenable to curative surgery have 5-year survival rates of ∼40% after pulmonary resection; however, 70% of patients present with unresectable disease, and their prognosis is extremely poor. Locoregionally advanced cases (unresectable stage III) are usually managed with radiotherapy. In patients with metastatic disease, median survival with the best available therapies, including supportive care, palliative radiotherapy and chemotherapy, is typically 6-10 months and most patients will die of cancer within 1-2 years following the initial diagnosis. The beneficial effects of chemotherapy, both in addition to radiotherapy in unresectable stage III NSCLC, or as a sole modality in stage IV disease, has been firmly established [2] .
The choice of active cytotoxic agents in the treatment of advanced NSCLC is limited. Vinorelbine, a novel vinca-alkaloid, has generated in large phase III trials a response rate of 12-20% and a median survival of 30 weeks [3] [4] [5] . The combination of vinorelbine and cisplatin is associated with response rates of 25-40% and a median survival of 33-40 weeks [4] [5] [6] . Traditionally, chemotherapy in NSCLC has been delivered intravenously. In an attempt to improve the comfort of patients, oral administrations have recently been investigated. The oral administration of active cytotoxic agents, apart from avoiding the peripheral vein irritation or discomfort of central venous access [7] , may also provide economic savings associated with a reduction in the number of hospital visits.
The clinical development of vinorelbine oral formulation started in 1994 with a phase I dose-finding study in patients with advanced breast cancer [8] . The maximum tolerated dose was set at 100 mg/m 2 weekly, and the recommended dose for further clinical investigations was 80 mg/m 2 weekly. Dose-limiting toxicities included neutropenia, nausea/vomiting and constipation due to autonomic neuropathy. Preliminary evidence of activity was demonstrated in first-and second-line chemotherapy of advanced breast cancer; there were six objective responses out of 14 evaluable patients administered doses of 80 or 100 mg/m 2 /week. A comparative cross-over oral/intravenous (i.v.) study showed that the bioavailability of the oral administration (soft-gelatin capsules; 80 mg/m 2 ) is 43 ± 14% of that with a 25 mg/m 2 i.v. infusion [9] . The range of doses administered was derived from the established bioequivalence between the i.v. and the oral formulation: 30 mg/m , respectively. A regimen with individual dose titra-tion according to the hematological tolerance was demonstrated to be efficient and safe [9, 10] . In a recent randomized phase II study in advanced NSCLC [11] , 115 patients with stage IIIB or IV disease were randomized (2 to 1) to receive oral vinorelbine at a dose of 60 mg/m 2 for the first three administrations and then escalated to 80 mg/m 2 /week in the absence of severe neutropenia, or i.v. vinorelbine at 30 mg/m 2 /week. After external panel review, the response rates in evaluable patients were 14% in the oral arm and 12% in the i.v. arm. The median progression-free survival with oral and i.v. vinorelbine was 3.2 and 2.1 months, respectively, and the median survival 9.3 and 7.9 months, respectively. Safety profile was qualitatively comparable in both arms.
Since platinum-based combinations are a standard of care for stage IIIB-IV NSCLC, the purpose of the present study was to evaluate the partial substitution of i.v. vinorelbine with its oral form in the established combination of vinorelbine plus cisplatin in advanced NSCLC. It should be noted that this was only a partial substitution due to the requirement for i.v. administration of cisplatin on day 1; venopuncture was avoided on days 8, 15 and 22 through the use of oral vinorelbine.
Patients and methods

Eligibility and evaluation
Eligibility criteria for this study were as follows: age from 18 to 75 years; histologically or cytologically confirmed NSCLC; inoperable stage IIIB or IV disease, or relapsed unresectable disease; Karnofsky performance status ≥80%; adequate bone marrow, liver and renal functions; and life expectancy of ≥12 weeks. Patients were eligible if they had received prior surgery or radiotherapy, provided that there were target lesions outside the irradiated area. Previous chemotherapy or immunotherapy were not permitted and at least one indicator lesion [according to World Health Organization (WHO) criteria] measurable by computed tomography (CT) scan and >20 × 10 mm was mandated. Exclusion criteria were as follows: pregnant/lactating women or those of child-bearing potential who were not using effective contraception; active central nervous system disorder or brain metastasis; symptomatic sensory neuropathy grade >1 according to National Cancer Institute-common toxicity criteria (NCI-CTC); clinically significant cardiovascular disease; active infection requiring i.v. antibiotics within 2 weeks; superior vena cava syndrome; long-term oxygen therapy; pre-existing symptomatic pleural effusion; ascites or pericardial effusion; concomitant neoplasm other than in situ cervical carcinoma or basal cell carcinoma of skin; radiotherapy within the last 4 weeks; concomitant treatment with any other anticancer agents; uncontrolled hypercalcemia; unstable concomitant disease; known hypersensitivity to drugs similar to the study medication; concomitant corticosteroids at doses greater than methylprednisolone 20 mg/day or equivalent; significant malabsorption or disease affecting gastrointestinal function; the presence of any psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol.
The study was conducted in accordance with the ethical principles set out in the Declaration of Helsinki (Somerset West amendment) and was approved by the ethics committees of all participating institutions. All patients who entered the study gave written informed consent according to the requirements of the national legislation of the country in which they were treated.
Pretreatment evaluation consisted of physical examination, complete blood count, biochemical screen, electrocardiogram, chest X-ray, CT of the chest, brain and liver (if positive by ultrasound) and bone scintigraphy (with direct imaging of areas of increased uptake). Other imaging procedures and audiometry were performed if clinically indicated. Hematological monitoring was performed weekly and biochemical screens were repeated with every chemotherapy cycle. All imaging procedures were repeated every two cycles. Quality of life (QoL) assessments based on the EORTC QLQ-C30 and QLQ-LC13 questionnaires were performed before study entry, before each cycle and at the end of the study. A patient was evaluable for one type of questionnaire if it was completed just before the administration of the corresponding cycle and could be compared with the baseline evaluable questionnaire.
Treatment plan
Cisplatin was administered at a dose of 100 mg/m 2 on day 1 of each cycle with prehydration according to routine practice of the individual center. Intravenous vinorelbine was supplied as a 10 mg/ml solution for injection on day 1 of each cycle at a dose of 25 mg/m 2 (capped to a maximum of 50 mg). The drug was reconstituted to a total volume of 50 ml with N-saline, and then given into the site injection port of a freely flowing saline infusion over 6-10 min; the saline infusion was continued to flush the vein. Oral vinorelbine was supplied as soft gel capsules containing either 30 or 40 mg of the active drug and was administered at 60 mg/m 2 (capped to a maximum of 120 mg) on days 8, 15
and 22 of each cycle. Treatment was planned to continue for a maximum of eight cycles unless halted by disease progression, unacceptable toxicity or patient refusal. Routine prophylactic antiemetics were administered to cover day 1 cisplatin/i.v. vinorelbine. Treatment was to be modified in the case of hematological and/or non-hematological toxicities according to a prespecified system. Hematological toxicity including neutropenia or thrombocytopenia at grade ≥2 on day 1 would result in treatment delay and reassessment after 1 week. On days 8, 15 or 22, the same levels of toxicity would result in the omission of the planned oral vinorelbine dose. Neurological toxicity at grade 2 would result in a 50% dose reduction, and at grade 3/4, in treatment discontinuation. Hepatic toxicity at grade 2 on day 1 would result in delay and reassessment 1 week later, and at grades 3 or 4, treatment would be discontinued. Renal toxicity was further assessed by creatinine clearance with modification of the cisplatin dose as follows: ≥55 ml/min, no modification; 45-54 ml/min, 50% dose reduction; <45 ml/min, delay of both vinorelbine and cisplatin and reassessment 1 week later. Toxicity affecting hearing at grade 2 would result in a 50% reduction of the cisplatin dose, and at grade 3/4, in treatment discontinuation. Doses were not modified for nausea/vomiting unless these symptoms could not be controlled by the appropriate antiemetic therapy.
Response and toxicity criteria
All eligible patients were considered evaluable for toxicity and response by an 'intention-to-treat' analysis. Response was assessed according to WHO criteria [12] with European Organisation for Research and Treatment of Cancer (EORTC) modifications [13] . In this study, the clinical response was additionally determined using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria [14] . All responses were reviewed by two independent radiologists. Toxicity was scored according to the NCI-CTC [15] . The design of Fleming [16] was used to determine the sample size of this two-stage phase II study; setting response rate limits of 15-35% and α and β error limits of <10%, the total sample size required was 40 evaluable patients. An evaluation was required after 20 evaluable patients, with recruitment to continue if four or more responses and fewer than seven responses had been seen. Response rate in the intention-to-treat and evaluable population were presented with their 95% confidence intervals (CIs). Time-dependent parameters were assessed using the Kaplan-Meier method. The cut-off date for the survival analysis was 1 March 2002.
Results
Patient characteristics
A total of 56 patients with NSCLC were enrolled in 10 centers from July 2000 to March 2001 (Table 1) . Forty-eight (86%) of the patients were male. Patient ages ranged from 40 to 74 years, with a median age of 60 years. Patients presented mainly with either squamous cell carcinoma (50%) or adenocarcinoma (27%). Approximately two-thirds of patients had metastatic disease at study entry and of the remaining patients with stage IIIB disease, 42% had pleural effusion. A total of 27% and 39% of patients had a Karnofsky score of 100% and 90%, respectively. Only 12.5% of patients had received prior surgery and no patient had received prior radiotherapy.
Treatment administration
A total of 226 cycles were administered during the study with a median of four cycles per patient (range 1-7). The median relative dose intensity of cisplatin and i.v. vinorelbine was 97% and 99%, respectively, whereas the median relative dose intensity of oral vinorelbine was 57%. As planned by the protocol, administrations of oral vinorelbine were canceled (and not delayed) on days 8, 15 and 22 in 23%, 63% and 22% of cycles, respectively (in most instances because of a neutrophil count <1.5 × 10 9 /l). Both cisplatin and i.v. vinorelbine scheduled on day 1 were delayed by up to 1 week in 8.2% of cycles and by 1-2 weeks in 2.4% of cycles; the cisplatin dose was reduced in 14% of cycles as a result of nonhematological toxicities (renal and hearing toxicities).
Treatment outcomes
One patient was ineligible according to the study entry criteria because of the presence of a brain metastasis at the time of inclusion. This patient's overall response after four cycles was progressive disease. An additional four patients were considered to be nonevaluable for response because they were taken off study before their first tumor evaluation (one died at home after cycle one, cause of death unknown, two were taken off study with renal impairment after cycle one and received alternative treatment and one patient died of febrile neutropenia during cycle two before tumor evaluation).
After review by an independent panel, 17 partial responses (WHO criteria) were scored: 30% (95% CI 18% to 42%) in the intention-to-treat analysis and 33% (95% CI 20% to 46%) in 51 evaluable patients (Table 2) . Scoring by RECIST criteria resulted in one change from a partial response by WHO criteria to no change. The median duration of follow-up was 14.8 months (range 11-19.5). The median progression-free survival was 5.5 months (95% CI 3.7-6.4 months) (Figure 1) , the median overall survival was 8.9 months (95% CI 8.8-11.7 months) (Figure 2) , and the 1-year survival probability was 37% (95% CI 24% to 50%). Twelve patients (21%) were treated with at least one further chemotherapy regimen.
Toxicity
Neutropenia was the main hematological toxicity and occurred in 88% of patients (grade 3-4 in 73% of patients) ( Table 3) . Five patients experienced febrile neutropenia, which was fatal in one case. Two patients experienced a neutropenic infection leading to study withdrawal. Growth factors were prescribed in only 7.1% of cycles. Neutropenia was most frequent and severe on day 15 of (21) 11 (22) Non-evaluable 4 (7.1) NA each cycle and was associated with a relatively high rate of canceled administrations on that day (63%). Anemia occurred frequently (88% of patients) but was rarely severe (blood transfusions were required in 6.6% of cycles). Typically for the cisplatin combination, gastrointestinal toxicities were the most frequent non-hematological toxicities (Table 4) . Grade 3-4 nausea and vomiting occurred in 8.9% of patients. It should be noted that prophylactic antiemetic therapy was given in only 8% of the oral vinorelbine administrations. Constipation was observed in 8.9% of patients and was never severe. Fatigue was frequent (45% of patients) but rarely severe. Neurosensory toxicity was observed in 16% of patients leading to study withdrawal for two patients after having received cisplatin 380 and 600 mg/m 2 , respectively. Episodes of severe renal insufficiency led to study withdrawal in three patients. Ototoxicity led to cisplatin reduction in two patients.
QoL evaluation
Forty-two patients completed the QoL questionnaires at inclusion. Thirty-four and 22 patients were evaluable for both questionnaires after the first and second cycles of therapy, respectively. Two analyses of the QLQ-C30 questionnaire were performed in two subpopulations, defined according to their compliance in filling in the questionnaire from cycle one to cycle two. As early withdrawal from the trial could correspond with a worsening of QoL, the evolution of each item was followed in these two different subpopulations.
In the first subpopulation, the comparison of functional score scales between baseline and the first evaluation showed a worsening of physical, role and social scores, the other items having slightly worsened. In the second subpopulation, functional scores were stable except for physical and social scores. The symptom scales showed an improvement of some lung-cancer specific symptoms (pain, dyspnea) and sleep disturbance. As expected with this combination, nausea/vomiting and diarrhea scales worsened in the two subpopulations. The item QoL remained globally stable.
The analysis of the QLQ-LC13 questionnaire in the two subpopulations showed stabilization, or a slight improvement, of all lung-cancer-specific items (dyspnea, coughing, hemoptysis, dysphagia and pain), whereas specific treatment-related toxicities (alopecia and peripheral neurosensory) worsened (Figure 3) .
Discussion
There has often been a perception by some physicians and patients that i.v. treatments are more effective than oral treatments. Until recently, oral cancer therapy in solid malignancies has mainly included hormonal agents. There are only a few chemotherapeutic agents available in oral form and their use has been limited. Liu et al. [7] indicated that ∼90% of cancer patients would prefer oral versus i.v. chemotherapy, predominantly because of the convenience of administration outside a clinical setting, as well as current concerns or previous problems with i.v. access. On the other hand, however, any oral formulation is preferred only provided its efficacy is maintained versus the i.v. route. For the reasons mentioned, the development of an 'all oral' regimen with equivalent safety and efficacy in the palliative setting would clearly be a very welcome addition to the chemotherapeutic armamentarium of NSCLC [17] .
In this phase II study, a response rate of 33% in the evaluable population was achieved after independent panel review. Other major outcomes included a median progression-free survival of 5.5 months, a median survival of 9 months and a 1-year survival probability of 37%. Previous phase II studies of i.v. vinorelbine in combination with cisplatin in a 4-week schedule showed overall response rates ranging from 33 to 42% (evaluable population) [18] [19] [20] [21] . However, response rates in these studies were not verified by independent panel review. Similar efficacy has also been shown in two large randomized phase III South West Oncology Group (SWOG) trials using i.v. vinorelbine and cisplatin [6, 19, 22] . Indeed, the first of them, including 206 NSCLC patients treated with i.v. vinorelbine 25 mg/m 2 /week and cisplatin 100 mg/m 2 , demonstrated a response rate of 26% (intention-to- treat analysis) with a median survival of 8 months [6] . Another study including 202 patients reported a response rate of 28% and a median survival of 8 months [22] . It should be noted that both studies included confirmed and unconfirmed responses.
The most frequent adverse events in our series were neutropenia and anemia, both observed in 88% of patients. Grade 3-4 neutropenia was reported in 73% of patients and was associated with complications in seven patients (five cases of febrile neutropenia leading to one death and two cases of neutropenic infection). Similar to the 4-week schedule using only i.v. vinorelbine [6] , a high incidence of vinorelbine cancellations (63%) was observed on day 15 of the cycle, secondary to a high rate of neutropenia on that day of the cycle. The relative dose intensity of oral vinorelbine was lower in comparison to that of i.v. vinorelbine and cisplatin. This could be explained by the dose-modification rules used in the present study. Indeed, no dose reduction of oral and i.v. vinorelbine was allowed and the drug could not be administered when the neutrophil count was <1500/mm 3 . Intravenous vinorelbine administrations could be delayed in cases of hematological toxicity, whereas oral vinorelbine administration could not be delayed and therefore was just canceled. On the other hand, in the two SWOG trials using cisplatin and i.v. vinorelbine [6, 22] , patients could receive a reduced dose when neutrophil counts were between 1000 and 1500/mm 3 . The most frequent non-hematological toxicities included nausea and vomiting. Grade 3-4 was observed in less than 10% of patients. Neurological symptoms occurred in 16% of patients and led to study withdrawal in two. Renal toxicities and ototoxicity, typical of cisplatin-based regimens, were rare but led to treatment discontinuation in three patients and dose reduction of cisplatin in another two. Importantly, no unexpected adverse events were reported. The toxicity profile of this combination was not different from that observed in the two SWOG trials using i.v. vinorelbine [6, 22] . Administration of oral chemotherapy has several potential advantages: greater patient convenience and acceptance, as well as significant cost savings, both in terms of treatment costs and lost wages incurred by patients and family during the physicians' visits [23] . In this study, oral vinorelbine had to be given in the presence of a physician or a nurse. No major treatment violations were observed. One advantage of oral vinorelbine is the onceweekly schedule that reduces the risk of lack of compliance. Indeed, poor patient compliance has been reported with a multiday oral regimen [24] . There is evidence that with regular patient education and monitoring, adequate patient compliance to oral medications may be achieved [17] . In the future, this may allow the prescribing oral vinorelbine as a home-based therapy, which would have social benefits and give the patient an increased feeling of control over their treatment.
In conclusion, this study has demonstrated that partial substitution of i.v. vinorelbine by its oral form in combination with cisplatin maintains the efficacy and safety of the standard 4-week regimen using i.v. vinorelbine exclusively [6, 22] . Given the relatively high number of oral vinorelbine omissions on day 15 of the 4-week cycle, an alternative option including cisplatin and i.v. vinorelbine on day 1 followed by oral vinorelbine on day 8 in a 3-weekly schedule warrants further evaluation, preferably in a randomized study with i.v. vinorelbine in the control arm. A desirable approach would be a fully oral vinorelbine regimen in combination with another active oral agent. Such an ambulatory administered regimen would clearly be a very welcome development in the palliative setting of NSCLC, provided its safety and efficacy are similar to standard i.v. combinations. In addition to the development in this indication, a range of clinical studies are in progress with paclitaxel, docetaxel, capecitabine and cyclophosphamide. Oral vinorelbine offers a new therapeutic option, both in monotherapy and in combination with traditional cytotoxic agents.
